Abstract：Progressive familial intrahepatic cholestasis type Ⅱ (PFIC-2) is an autosomal recessive disorder caused by biallelic variants of ABCB11 gene. This paper reports the clinical and laboratory features of a pediatric patient with PFIC-2. The patient was a 2.4-month-old male infant with jaundice and hepatomegaly as the main clinical manifestations. The serum levels of total bilirubin, direct bilirubin and total bile acids were increased, while the serum γ-glutamyl transpeptidase (GGT) level was normal. Next generation sequencing revealed two missense variants, c.1493T > C(p.Ile498Thr) and c.1502T > G(p.Val501Gly), in the ABCB11 gene of the patient, which were inherited from his father and mother, respectively. The latter was a novel variant which was predicted to be pathogenic by using a variety of bioinformatic tools, and the affected p.Val501 residue was highly conserved in 112 homologous peptides.
LIN Gui-Zhi,QIU Jian-Wu,CHENG Ying et al. Clinical and genetic analysis of an infant with progressive familial intrahepatic cholestasis type II[J]. CJCP, 2018, 20(9): 758-764.
Vitale G, Gitto S1, Raimondi F, et al. Cryptogenic cholestasis in young and adults:ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing[J]. J Gastroenterol, 2018, 53(8):945-958.
Brinkert F, Pukite I, Krebs-Schmitt D, et al. Allogeneic hematopoietic stem cell transplantation eliminates alloreactive inhibitory antibodies after liver transplantation for bile salt export pump deficiency[J]. J Hepatol, 2018, https://doi.org/10.1016/j.jhep.2018.06.003.
[7]
Alsalloom A. Hepatocellular carcinoma in a boy with progressive familial intrahepatic cholestasis type Ⅱ:Challenging identification:Case report[J]. Int J Health Sci (Qassim), 2013, 7(2):252-255.
[8]
Dröge C, Schaal H, Engelmann G, et al. Exon-skipping and mRNA decay in human liver tissue:molecular consequences of pathogenic bile salt export pump mutations[J]. Sci Rep, 2016, 6:24827.
Lam CW, Cheung KM, Tsui MS, et al. A patient with novel ABCB11 gene mutations with phenotypic transition between BRIC2 and PFIC2[J]. J Hepatol, 2006, 44(1):240-242.
[15]
Gomez-Ospina N, Potter CJ, Xiao R, et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis[J]. Nat Commun, 2016, 7:10713.
Qiu YL, Gong JY, Feng JY, et al. Defects in myosin VB are associated with a spectrum of previously undiagnosed low γ-glutamyltransferase cholestasis[J]. Hepatology, 2017, 65(5):1655-1669.
[18]
van Mil SW, van der Woerd WL, van der Brugge G, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11[J]. Gastroenterology, 2004, 127(2):379-384.
Strautnieks SS, Bull LN, Knisely AS, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis[J]. Nat Genet, 1998, 20(3):233-238.
[21]
Jacquemin E, Hermans D, Myara A, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis[J]. Hepatology, 1997, 25(3):519-523.
[22]
Stapelbroek JM, van Erpecum KJ, Klomp LW, et al. Liver disease associated with canalicular transport defects:current and future therapies[J]. J Hepatol, 2010, 52(2):258-271.
[23]
Misawa T, Hayashi H, Sugiyama Y, et al. Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2[J]. Bioorg Med Chem, 2012, 20(9):2940-2949.
[24]
Wang L, Dong H, Soroka CJ, et al. Degradation of the bile salt export pump at endoplasmic reticulum in progressive familial intrahepatic cholestasis type Ⅱ[J]. Hepatology, 2008, 48(5):1558-1569.
[25]
Nagasaka H, Yorifuji T, Hirano K, et al. Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis[J]. Metabolism, 2009, 58(1):48-54.
[26]
Aydogdu S, Cakir M, Arikan C, et al. Liver transplantation for progressive familial intrahepatic cholestasis:clinical and histopathological findings, outcome and impact on growth[J]. Pediatr Transplant, 2007, 11(6):634-640.
[27]
Kubitz R, Dröge C, Kluge S, et al. Autoimmune BSEP disease:disease recurrence after liver transplantation for progressive familial intrahepatic cholestasis[J]. Clin Rev Allergy Immunol, 2015, 48(2-3):273-284.
